FoB update – Europe’s CHMP approved another biosimilar yesterday: an Epogen knockoff from Stada that will be marketed in most EU countries by Hospira (the spin-off from ABT). <A HREF="http://biz.yahoo.com/prnews/071019/aqf038.html?.v=22" target="_blank">http://biz.yahoo.com/prnews/071019/aqf038.html?.v=22</A>